Corrigendum to “HPV16 DNA status is a strong prognosticator of loco-regional control after postoperative radiochemotherapy of locally advanced oropharyngeal carcinoma: Results from a multicentre explorative study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG)” [Radiother. Oncol. 113 (2014) 317–323]
Year: 2015
Type: erratum
Abstract: The authors regret that in the above-mentioned article an error occurred. In the original manuscript, it was stated that patients who were treated between 2005 and 2010 with a curatively intended cisplatin based PORT-C were included in this retrospective study. The correct statement is that patients who were treated between 2004 and 2012 with a curatively intended cisplatin based PORT-C were included in this retrospective study. In each centre, the patients were included backwards from 2010 to 2005 or from 2012 to 2004 as HPV prevalence is increasing in recent years. All results presented in the manuscript remain unaffected. HPV16 DNA status is a strong prognosticator of loco-regional control after postoperative radiochemotherapy of locally advanced oropharyngeal carcinoma: Results from a multicentre explorative study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG)Radiotherapy and OncologyVol. 113Issue 3PreviewTo investigate the impact of HPV status in patients with locally advanced head and neck squamous cell carcinoma (HNSCC), who received surgery and cisplatin-based postoperative radiochemotherapy. Full-Text PDF Open Access
Source: Radiotherapy and Oncology
Authors: Fabian Lohaus, Annett Linge, Inge Tinhofer, Volker Budach, Eleni Gkika, Martin Stuschke, Panagiotis Balermpas, Claus Rödel, Melanie Avlar, Anca-Ligia Grosu, Amir Abdollahi, Jürgen Debus, Christine Bayer, Claus Belka, Steffi Pigorsch, Stephanie E. Combs, David Mönnich, Daniel Zips, Cläre von Neubeck, Gustavo B. Baretton, Steffen Löck, Howard D. Thames, Mechthild Krause, Michael Baumann
Institutions: German Cancer Research Center, OncoRay, University Hospital Carl Gustav Carus, Deutsches Konsortium für Translationale Krebsforschung, German Cancer Consortium (DKTK) Dresden, Technische Universität Dresden, Stiftung Charité, Charité – Universitätsmedizin Berlin, University of Duisburg-Essen, Goethe University Frankfurt, University of Freiburg, Heidelberg University, National Center for Tumor Diseases, Ludwig-Maximilians-Universität München, Technical University of Munich, University of Tübingen, The University of Texas MD Anderson Cancer Center, Helmholtz-Zentrum Dresden-Rossendorf
Language: English
Topic: Head and Neck Cancer Studies
Subfield: Otorhinolaryngology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $3,770
OpenAlex ID: W2007134847